Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes.
Orli Friedman-EldarTolga OzmenSalah James El HaddiNeha GoelYouley TjendraSusan B KesmodelMecker G MollerDido FranceschiChristina LaytonEli AvisarPublished in: Annals of surgical oncology (2022)
For patients with node-positive, ER+, HER2- breast cancer, a lower burden of disease at the time of diagnosis (stage II) is associated with a significantly higher axillary pCR, enabling those patients to be spared axillary dissection. Further studies are necessary to define the role of genomic profiling in predicting axillary response.
Keyphrases
- lymph node
- estrogen receptor
- epidermal growth factor receptor
- sentinel lymph node
- neoadjuvant chemotherapy
- end stage renal disease
- tyrosine kinase
- ultrasound guided
- rectal cancer
- newly diagnosed
- endothelial cells
- ejection fraction
- advanced non small cell lung cancer
- locally advanced
- chronic kidney disease
- early stage
- stem cells
- type diabetes
- radiation therapy
- gene expression
- prognostic factors
- neuropathic pain
- squamous cell carcinoma
- radical prostatectomy
- skeletal muscle
- prostate cancer
- endoplasmic reticulum
- patient reported outcomes
- peritoneal dialysis
- spinal cord injury
- mesenchymal stem cells
- robot assisted
- metabolic syndrome
- bone marrow
- copy number
- dna methylation